Abstract
ABSTRACT: Two mutations in the lysosomal α-glucosidase gene, a single base pair deletion (ΔT525) and a deletion of exon 18, have recently been identified with a relatively high incidence in Caucasian patients with glycogen storage disease type II (GSD II). Prenatal diagnosis was made in a pregnancy of consanguineous parents of a child with GSD II. The ΔT525 deletion was demonstrated in this family but unexpectedly in only one of the parents. The absence of the ΔT525 deletion in DNA isolated from the chorionic villi and a normal α-glucosidase activity indicated that the fetus was not affected. The possible role of mutation analysis in the prenatal diagnosis of GSD II is discussed in the light of our previous experience from a series of 100 prenatal diagnoses for this disorder by enzyme analysis.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kleijer, W., Der Kraan, M., Kroos, M. et al. Prenatal Diagnosis of Glycogen Storage Disease Type II: Enzyme Assay or Mutation Analysis?. Pediatr Res 38, 103–106 (1995). https://doi.org/10.1203/00006450-199507000-00018
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1203/00006450-199507000-00018
This article is cited by
-
Antenatal diagnosis of pompe disease by fetal echocardiography: impact on outcome after early initiation of enzyme replacement therapy
Journal of Inherited Metabolic Disease (2010)
-
Early administration of enzyme replacement therapy for Pompe disease: Short‐term follow‐up results
Journal of Inherited Metabolic Disease (2008)
-
Prenatal diagnosis of Pompe disease by electron microscopy
Archives of Gynecology and Obstetrics (2005)